

# Samir Abu-Rumeileh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7483302/publications.pdf>

Version: 2024-02-01

220  
papers

12,305  
citations

27035

58  
h-index

38517

99  
g-index

226  
all docs

226  
docs citations

226  
times ranked

15374  
citing authors

#	ARTICLE	IF	CITATIONS
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	0.7	18
2	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	0.9	7
3	Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. <i>Journal of Neural Transmission</i> , 2022, 129, 207-230.	1.4	26
4	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	3.7	27
5	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum $\alpha$ NfL and $\beta$ pNfH: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	2.8	21
6	Diagnostic and Prognostic Blood Biomarkers in Transient Ischemic Attack and Minor Ischemic Stroke: An Up-To-Date Narrative Review. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106292.	0.7	5
7	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	3.0	4
8	Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1664.	1.8	11
9	A one-year longitudinal evaluation of cerebrospinal fluid and blood neurochemical markers in a patient with cryptococcal meningitis complicated by ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120090.	0.3	3
10	Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 422-435.	0.9	22
11	Blood $\beta$ -Synuclein and Neurofilament Light Chain During the Course of Prion Disease. <i>Neurology</i> , 2022, , 10.1212/WNL.000000000200002.	1.5	11
12	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	1.1	2
13	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. <i>Movement Disorders</i> , 2022, 37, 669-683.	2.2	30
14	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. <i>Nature Reviews Neurology</i> , 2022, 18, 158-172.	4.9	205
15	Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldt-Jakob Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2051.	1.8	5
16	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	1.5	1
17	Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1553-1561.	1.4	20
18	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	1.8	1

#	ARTICLE	IF	CITATIONS
19	The CBLA detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	1.7	1
20	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. <i>Biomolecules</i> , 2022, 12, 440.	1.8	5
21	Serum Beta $\beta$ Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. <i>Annals of Neurology</i> , 2022, 92, 6-10.	2.8	9
22	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	0.9	12
23	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
24	Acute stroke-like deficits associated with nonketotic hyperglycemic hyperosmolar state: an illustrative case and systematic review of literature. <i>Neurological Sciences</i> , 2022, 43, 4671-4683.	0.9	5
25	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 62.	3.0	9
26	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.5	5
27	Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. <i>Neurotherapeutics</i> , 2022, 19, 1248-1258.	2.1	46
28	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 659-667.	0.9	21
29	Factors associated with mortality in early stages of parkinsonism. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	4
30	Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 492-497.	2.2	12
31	Fluid biomarkers in frontotemporal dementia: past, present and future. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 204-215.	0.9	62
32	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.4	31
33	Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. <i>Journal of Neurology</i> , 2021, 268, 1133-1170.	1.8	286
34	Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt traumatic brain injury. <i>Burns and Trauma</i> , 2021, 9, ttab027.	2.3	4
35	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	2.8	42
36	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 276-286.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. <i>Zeitschrift Fur Medizinische Physik</i> , 2021, 31, 37-47.	0.6	1
38	Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art. <i>Frontiers in Neuroscience</i> , 2021, 15, 648743.	1.4	14
39	Protein Binding Partners of Dysregulated miRNAs in Parkinson's Disease Serum. <i>Cells</i> , 2021, 10, 791.	1.8	11
40	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 946-958.	0.4	16
41	Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, e44-e44.	3.7	6
42	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	1.2	18
43	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 521-534.	5.3	64
44	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2021, 15, 679199.	1.4	66
45	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. <i>Cortex</i> , 2021, 140, 66-79.	1.1	10
46	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	3.0	12
47	The clinical spectrum of multisystem proteinopathy: Data from a neurodegenerative cohort. <i>Journal of the Neurological Sciences</i> , 2021, 426, 117478.	0.3	3
48	Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 330.	1.2	12
49	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. <i>Translational Neurodegeneration</i> , 2021, 10, 31.	3.6	18
50	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	1.5	3
51	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. <i>Journal of Psychiatric Research</i> , 2021, 144, 54-58.	1.5	34
52	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	1.4	8
53	Clinico-genetic findings in 509 frontotemporal dementia patients. <i>Molecular Psychiatry</i> , 2021, 26, 5824-5832.	4.1	23
54	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1153-1161.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Varicella-Zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. <i>Journal of Neurology</i> , 2021, , 1.	1.8	10
56	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. <i>Expert Review of Proteomics</i> , 2021, 18, 977-994.	1.3	5
57	Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1. <i>Sleep</i> , 2020, 43, .	0.6	6
58	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. <i>Journal of Neurology</i> , 2020, 267, 36-44.	1.8	47
59	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 40-48.	0.9	16
60	Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2020, 139, 119-134.	3.9	73
61	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. <i>Lancet Psychiatry</i> , 2020, 7, 93-108.	3.7	252
62	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 2.	3.0	86
63	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , 2020, 19, 145-156.	4.9	175
64	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. <i>Clinica Chimica Acta</i> , 2020, 502, 199-200.	0.5	0
65	Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. <i>NeuroImage: Clinical</i> , 2020, 25, 102112.	1.4	10
66	Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 148-154.	1.3	18
67	Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections. <i>Cells</i> , 2020, 9, 2169.	1.8	3
68	Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA. <i>Journal of Virological Methods</i> , 2020, 286, 113965.	1.0	10
69	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. <i>Scientific Reports</i> , 2020, 10, 8776.	1.6	4
70	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	0.9	12
71	Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement. <i>European Journal of Neurology</i> , 2020, 27, 2378-2380.	1.7	51
72	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1007-1009.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Dipeptide repeat protein and TDP-43 pathology along the hypothalamic-pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. <i>Acta Neuropathologica</i> , 2020, 140, 777-781.	3.9	8
74	Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117106.	0.3	17
75	Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1181-1188.	0.9	34
76	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	1.5	20
77	Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers and cognitive performance. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	0.4	1
78	Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. <i>BMC Neurology</i> , 2020, 20, 227.	0.8	6
79	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458.	1.1	15
80	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , 2020, 15, 36.	4.4	46
81	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 503-511.	0.9	33
82	Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1699-1708.	1.8	39
83	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2020, 19, 1310-1318.	1.8	43
84	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	0.9	106
85	CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 191-199.	1.7	16
86	S-ketamine induces acute changes in the proteome of the mouse amygdala. <i>Journal of Proteomics</i> , 2020, 216, 103679.	1.2	6
87	CSF Ubiquitin Levels Are Higher in Alzheimer's Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. <i>Biomolecules</i> , 2020, 10, 497.	1.8	8
88	Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes. <i>Acta Neuropathologica Communications</i> , 2020, 8, 61.	2.4	58
89	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	0.9	55
90	Guillain-Barré syndrome following COVID-19: new infection, old complication?. <i>Journal of Neurology</i> , 2020, 267, 1877-1879.	1.8	171

#	ARTICLE	IF	CITATIONS
91	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	1.1	26
92	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 144.	2.4	20
93	Antemortem CSF A $\beta$ <sub>42</sub> /A $\beta$ <sub>40</sub> ratio predicts Alzheimer's disease pathology better than A $\beta$ <sub>42</sub> in rapidly progressive dementias. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 263-273.	1.7	31
94	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 114.	2.4	11
95	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4674.	1.8	26
96	Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. <i>Clinica Chimica Acta</i> , 2019, 498, 148-153.	0.5	7
97	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	4.9	128
98	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. <i>Brain</i> , 2019, 142, e67-e67.	3.7	1
99	Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1068.2-1069.	0.9	44
100	Diagnostic value of surrogate CSF biomarkers for Creutzfeldtâ€“Jakob disease in the era of RT-QuIC. <i>Journal of Neurology</i> , 2019, 266, 3136-3143.	1.8	44
101	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimerâ€™s Disease and Correlates with Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 481-488.	1.2	171
102	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. <i>Translational Psychiatry</i> , 2019, 9, 54.	2.4	28
103	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984605.	1.5	41
104	Advantages and disadvantages of the use of the CSF Amyloid $\beta$ (A $\beta$ ) <sub>42</sub> /A $\beta$ <sub>40</sub> ratio in the diagnosis of Alzheimerâ€™s Disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 34.	3.0	325
105	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. <i>Frontiers in Immunology</i> , 2019, 10, 641.	2.2	34
106	Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 723-733.	1.2	21
107	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. <i>Neurology</i> , 2019, 92, e1479-e1486.	1.5	100
108	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. <i>Cortex</i> , 2019, 117, 33-40.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. <i>Journal of Psychiatric Research</i> , 2019, 113, 137-140.	1.5	81
110	A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. <i>Scientific Reports</i> , 2019, 9, 2918.	1.6	91
111	Different aspects of Alzheimer's disease-related amyloid $\beta$ -peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. <i>Acta Neuropathologica Communications</i> , 2019, 7, 178.	2.4	29
112	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. <i>Frontiers in Neurology</i> , 2019, 10, 1179.	1.1	18
113	Transverse Sinus Stenosis in Refractory Chronic Headache Patients: An Observational Study. <i>Frontiers in Neurology</i> , 2019, 10, 1287.	1.1	7
114	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	1.4	27
115	Neurochemical biomarkers in amyotrophic lateral sclerosis. <i>Current Opinion in Neurology</i> , 2019, 32, 747-757.	1.8	24
116	A Review on MS-Based Blood Biomarkers for Alzheimer's Disease. <i>Neurology and Therapy</i> , 2019, 8, 113-127.	1.4	35
117	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 4-10.	0.9	96
118	Biomarkers for diseases with TDP-43 pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 43-59.	1.0	38
119	Microchip Electrophoresis with Respect to Profiling of $A\beta$ Peptides in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2019, 1855, 327-340.	0.4	4
120	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 157-164.	0.9	174
121	Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 12-18.	1.1	7
122	The applause sign in frontotemporal lobar degeneration and related conditions. <i>Journal of Neurology</i> , 2019, 266, 330-338.	1.8	15
123	Story of the ALS-FTD continuum retold: rather two distinct entities. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 586-589.	0.9	26
124	Analysis of CACNA1A CAG repeat lengths in patients with familial ALS. <i>Neurobiology of Aging</i> , 2019, 74, 235.e5-235.e8.	1.5	6
125	Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 318-323.	1.8	1
126	The cryo-electron microscopy structure of huntingtin. <i>Nature</i> , 2018, 555, 117-120.	13.7	125



#	ARTICLE	IF	CITATIONS
127	Hot-spot KIF5A mutations cause familial ALS. <i>Brain</i> , 2018, 141, 688-697.	3.7	167
128	Relationship between cerebrospinal fluid concentrations of orexin A/hypocretin-1 and body composition in humans. <i>Peptides</i> , 2018, 102, 26-30.	1.2	5
129	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2018, 67, 21-22.	1.5	6
130	Comprehensive analysis of the mutation spectrum in 301 German ALS families. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 817-827.	0.9	80
131	Identification of rare genetic variants in Italian patients with dementia by targeted gene sequencing. <i>Neurobiology of Aging</i> , 2018, 66, 180.e23-180.e31.	1.5	18
132	The molecular tweezer CLR01 inhibits Ebola and Zika virus infection. <i>Antiviral Research</i> , 2018, 152, 26-35.	1.9	31
133	Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Caroline Moreau <i>et al</i> . 2018; Published by Mary Ann Liebert, Inc. This Open Access article distributed under the terms of the Creative Commons License ( <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a> ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 742-748.	2.5	86
134	Comment: Tau CSF proteins for diagnosis but tau PET imaging for AD diagnosis and staging. <i>Neurology</i> , 2018, 90, 216-216.	1.5	1
135	Online Preconcentration in Capillaries by Multiple Large-Volume Sample Stacking: An Alternative to Immunoassays for Quantification of Amyloid Beta Peptides Biomarkers in Cerebrospinal Fluid. <i>Analytical Chemistry</i> , 2018, 90, 2555-2563.	3.2	25
136	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. <i>Human Molecular Genetics</i> , 2018, 27, 706-715.	1.4	30
137	Rapidly Progressive Alzheimer's Disease: Contributions to Clinical-Pathological Definition and Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 887-897.	1.2	16
138	Alpha-synuclein is present in dental calculus but not altered in Parkinson's disease patients in comparison to controls. <i>Journal of Neurology</i> , 2018, 265, 1334-1337.	1.8	1
139	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 41.	3.0	8
140	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
141	Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. <i>Acta Neuropathologica</i> , 2018, 135, 681-694.	3.9	70
142	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
143	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 90, e22-e30.	1.5	148
144	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 239-247.	0.9	89

#	ARTICLE	IF	CITATIONS
145	Clinical Reasoning: Rapidly progressive dementia in a patient with HIV after an exotic journey. <i>Neurology</i> , 2018, 91, e1360-e1364.	1.5	1
146	Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 551-563.	1.2	46
147	Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. <i>Acta Neuropathologica Communications</i> , 2018, 6, 108.	2.4	107
148	Serum neurofilament light chain in behavioral variant frontotemporal dementia. <i>Neurology</i> , 2018, 91, e1390-e1401.	1.5	85
149	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A $\beta$ 2 species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	1.4	11
150	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. <i>PLoS ONE</i> , 2018, 13, e0197329.	1.1	68
151	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , 2018, 14, 577-589.	4.9	1,177
152	Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges. <i>Annals of Neurology</i> , 2018, 84, 347-360.	2.8	31
153	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 11.	1.7	34
154	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	1.7	40
155	Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD). <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 47.	1.7	13
156	Idiopathic Intracranial Hypertension Without Papilledema (IIHWOP) in Chronic Refractory Headache. <i>Frontiers in Neurology</i> , 2018, 9, 503.	1.1	28
157	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4301-4319.	2.4	34
158	The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 3.	3.0	76
159	Semen inhibits Zika virus infection of cells and tissues from the anogenital region. <i>Nature Communications</i> , 2018, 9, 2207.	5.8	41
160	Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2018, 17, 516-523.	1.8	23
161	Predicting primary progressive aphasia with support vector machine approaches in structural MRI data. <i>NeuroImage: Clinical</i> , 2017, 14, 334-343.	1.4	42
162	Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and A $\beta$ 242 levels. <i>Acta Neuropathologica</i> , 2017, 133, 559-578.	3.9	129

#	ARTICLE	IF	CITATIONS
163	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasia. <i>Neurology</i> , 2017, 88, 961-969.	1.5	73
164	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. <i>NeuroImage: Clinical</i> , 2017, 14, 656-662.	1.4	64
165	Poly(ADP-ribose) GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. <i>EMBO Molecular Medicine</i> , 2017, 9, 859-868.	3.3	90
166	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. <i>Expert Review of Proteomics</i> , 2017, 14, 499-514.	1.3	26
167	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113
168	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108
169	Neurofilaments in blood. <i>Neurology</i> , 2017, 89, 2126-2127.	1.5	0
170	Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected Procedures. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2297-2303.	1.1	136
171	Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. <i>Neurodegenerative Diseases</i> , 2017, 17, 227-234.	0.8	42
172	Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. <i>Expert Review of Proteomics</i> , 2017, 14, 769-777.	1.3	27
173	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 17.	3.0	30
174	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 112-119.	1.1	63
175	Superficial siderosis associated with peripheral autonomic failure and tetraventricular hydrocephalus: a case report. <i>Clinical Autonomic Research</i> , 2017, 27, 63-66.	1.4	1
176	Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay. <i>High-Throughput</i> , 2017, 6, 18.	4.4	8
177	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2015-311387.	0.9	207
178	TDP43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. <i>EMBO Journal</i> , 2016, 35, 2350-2370.	3.5	76
179	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. <i>Scientific Reports</i> , 2016, 6, 26145.	1.6	24
180	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. <i>Scientific Reports</i> , 2016, 6, 38737.	1.6	81

#	ARTICLE	IF	CITATIONS
181	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 954-960.	1.8	13
182	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 404-413.	1.1	84
183	Amyloid $\beta$ oligomerization is associated with the generation of a typical peptide fragment fingerprint. <i>Alzheimer's and Dementia</i> , 2016, 12, 996-1013.	0.4	17
184	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta$ 2 in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
185	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. <i>Cortex</i> , 2016, 83, 124-135.	1.1	21
186	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3126-3138.	2.5	92
187	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German "Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	1.8	46
188	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2016, 79, 152-158.	2.8	188
189	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. <i>Movement Disorders</i> , 2016, 31, 848-860.	2.2	52
190	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. <i>Journal of Neurochemistry</i> , 2016, 138, 184-192.	2.1	26
191	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	1.7	207
192	Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1353-1356.	1.5	2
193	Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and A $\beta$ 242 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1471-1480.	1.2	40
194	Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1 $\beta$ . <i>BMC Neurology</i> , 2016, 16, 185.	0.8	64
195	Aggregated $\beta$ -Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>American Journal of Pathology</i> , 2016, 186, 2152-2161.	1.9	17
196	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTL. <i>Journal of Neural Transmission</i> , 2016, 123, 289-296.	1.4	26
197	<i>NEK1</i> mutations in familial amyotrophic lateral sclerosis. <i>Brain</i> , 2016, 139, e28-e28.	3.7	105
198	Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2016, 11, e0164953.	1.1	21

#	ARTICLE	IF	CITATIONS
199	An integrated microfluidic chip for immunocapture, preconcentration and separation of $\beta^2$ -amyloid peptides. <i>Biomicrofluidics</i> , 2015, 9, 054117.	1.2	35
200	Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay. <i>Scientific Reports</i> , 2015, 5, 12767.	1.6	5
201	Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 17565-17588.	1.8	20
202	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 757-768.	1.1	21
203	Serum microRNAs in sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2015, 36, 2660.e15-2660.e20.	1.5	64
204	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.4	152
205	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. <i>Nature Neuroscience</i> , 2015, 18, 631-636.	7.1	652
206	Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e88680.	1.1	75
207	Intact Protein Analysis of Ubiquitin in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Differences in Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Proteome Research</i> , 2014, 13, 4518-4525.	1.8	41
208	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. <i>Brain</i> , 2014, 137, 2938-2950.	3.7	91
209	P1-163: DIFFERENTIAL SIALYLATION OF SERPIN A1, DETECTED BY NANOSCALE CAPILLARY ISOELECTRIC FOCUSING IN CEREBROSPINAL FLUID, AS AN EARLY DIAGNOSTIC MARKER OF PARKINSON'S DISEASE DEMENTIA. , 2014, 10, P360-P360.		0
210	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
211	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.1	1
212	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 1-10.	2.3	81
213	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2012, 7, e48783.	1.1	37
214	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. <i>Proteomics</i> , 2010, 10, 81-89.	1.3	39
215	Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 541-551.	1.2	74
216	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. <i>Methods</i> , 2008, 44, 289-298.	1.9	38

#	ARTICLE	IF	CITATIONS
217	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. <i>Neurobiology of Aging</i> , 2006, 27, 10-15.	1.5	69
218	Neurochemical diagnosis of Alzheimer's dementia by CSF A $\beta$ 242, A $\beta$ 242/A $\beta$ 240 ratio and total tau. <i>Neurobiology of Aging</i> , 2004, 25, 273-281.	1.5	267
219	?-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 2003, 54, 263-267.	2.8	82
220	Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 324-32.	1.4	65